- Home
- TARS vs TILE Comparison
TARS vs TILE Comparison
Compare TARS & TILE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | TILE |
|---|---|---|
| Founded | 2016 | 1973 |
| Country | United States | United States |
| Employees | N/A | 3570 |
| Industry | Medicinal Chemicals and Botanical Products | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TARS | TILE |
|---|---|---|
| Price | $69.20 | $37.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $89.00 | $36.00 |
| AVG Volume (30 Days) | ★ 831.4K | 407.2K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.29% |
| EPS Growth | ★ 48.21 | 32.43 |
| EPS | N/A | ★ 1.28 |
| Revenue | $451,360,000.00 | ★ $1,386,854,000.00 |
| Revenue This Year | $56.43 | $6.72 |
| Revenue Next Year | $30.19 | $5.61 |
| P/E Ratio | ★ N/A | $30.26 |
| Revenue Growth | ★ 146.71 | 5.41 |
| 52 Week Low | $48.20 | $24.40 |
| 52 Week High | $85.25 | $40.50 |
Technical Indicators
Market Signals| Indicator | TARS | TILE |
|---|---|---|
| Relative Strength Index (RSI) | 65.51 | 64.59 |
| Support Level | $60.95 | $27.29 |
| Resistance Level | $73.45 | $40.50 |
| Average True Range (ATR) | 3.30 | 1.30 |
| MACD | 1.12 | 0.36 |
| Stochastic Oscillator | 84.67 | 64.25 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).